Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.69 USD | -1.40% | +4.39% | +34.56% |
Financials (USD)
Sales 2024 * | 98.05M | Sales 2025 * | 83.06M | Capitalization | 83.53M |
---|---|---|---|---|---|
Net income 2024 * | -94M | Net income 2025 * | -48M | EV / Sales 2024 * | 0.37 x |
Net cash position 2024 * | 47.51M | Net cash position 2025 * | 57.37M | EV / Sales 2025 * | 0.31 x |
P/E ratio 2024 * |
-0.88
x | P/E ratio 2025 * |
-2.02
x | Employees | 225 |
Yield 2024 * |
286% | Yield 2025 * |
286% | Free-Float | 94.1% |
Latest transcript on Atara Biotherapeutics, Inc.
1 day | -1.40% | ||
1 week | -1.06% | ||
Current month | -0.58% | ||
1 month | -1.43% | ||
3 months | +12.34% | ||
6 months | -44.80% | ||
Current year | +34.56% |
Managers | Title | Age | Since |
---|---|---|---|
Pascal Touchon
CEO | Chief Executive Officer | 61 | 19-06-23 |
Eric Hyllengren
DFI | Director of Finance/CFO | - | 17-12-31 |
Anhco Nguyen
CTO | Chief Tech/Sci/R&D Officer | 51 | 21-05-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Carol Gallagher
CHM | Chairman | 59 | 12-12-31 |
Eric Dobmeier
BRD | Director/Board Member | 55 | 15-03-25 |
William Heiden
BRD | Director/Board Member | 64 | 15-11-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.03% | 0 M€ | 0.00% | - | |
0.03% | 509 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 0.69 | -1.40% | 526,311 |
24-04-25 | 0.6998 | -2.08% | 866,587 |
24-04-24 | 0.7147 | -0.54% | 697,941 |
24-04-23 | 0.7186 | +3.04% | 833,904 |
24-04-22 | 0.6974 | +5.51% | 856,889 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+34.56% | 83.53M | |
-2.31% | 103B | |
+0.56% | 95.71B | |
+1.69% | 22.02B | |
-17.37% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.85% | 15.52B | |
+3.21% | 13.86B | |
+33.54% | 12.04B |
- Stock Market
- Equities
- ATRA Stock